

Versione del curriculum vitae redatta in modo da garantire la conformità del medesimo a quanto prescritto dall'art. 4 del Codice in materia di protezione dei dati personali e dall'art. 26 d.lgs. 14 marzo 2013 n. 33/2013

Decreto Rettore Università di Roma "La Sapienza" n 2636/2018 del 07.11.2018

ANDREA VECCHIONE  
Curriculum Vitae  
AI FINI DELLA PUBBLICAZIONE

Rome  
28/11/2018

**Part I – Education**

Type	Year	Institution	Notes (Degree Experience,...)
University graduation	1995	Sapienza University of Rome	Medical Doctor
Licensure 01	1995	Sapienza University of Rome	Professional Practice Examination
Specialty	1999	Sapienza University of Rome	Residency in Surgical Pathology
Licensure 02	2013	ANVUR	Qualification as Full Professor 06/A4
Licensure 03	2013	ANVUR	Qualification as Full Professor 06/N1

**Part II – Appointments**

IIA – Academic Appointments

Start	End	Institution	Position
2001	2007	Sapienza University of Rome	Assistant Professor (MED/08)
2007	Present	Sapienza University of Rome	Associate Professor (MED/46)
2002	2005	Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, USA	Assistant Professor, Dept. of Urology and Microbiology.
2005	Present	The OHIO State University	Visiting Research Assistant Professor, Dept. of Human Cancer Genetics

IIB – Other Appointments

Start	End	Institution	Position
1998	2002	Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, USA	Research Fellowship
2004	Present	University Hospital Sant'Andrea	Attending Pathologist.

IIC – Reviewer/Editorial Board Appointments



Start	End	Journal	Position
2000	2004	American Journal of Pathology (IF 6.441 J. Citation Report)	Reviewer
2000	Present	Clinical Cancer Research (IF 10.199 J. Citation Report)	Reviewer
2000	Present	Cancer Research(IF 9.130 J. Citation Report)	Reviewer
2000	Present	Oncogene (IF 6.854 J. Citation Report)	Reviewer
2000	Present	Journal of Cellular Physiology(IF 3.923 J. Citation Report)	Reviewer
2000	Present	International Journal of Cancer(IF 7.360 J. Citation Report)	Reviewer
2000	Present	Journal of Urology (IF 5.381 J. Citation Report)	Reviewer
2009	2012	Journal of nucleic acid investigation (IF N/A J. Citation Report)	Associate Editor
2010	Present	Frontiers in Genetics (IF 4.151 J. Citation Report)	Reviewer Editor
2010	2016	Journal of Biomedicine and Biotechnology (IF 3.169 J. Citation Report)	Leading Guest Editor: Animals Models of Human Pathology
2010	Present	Frontiers in Molecular Biosciences (IF N/A J. Citation Report)	Reviewer Editor
2011	2016	Oncotarget (IF 5.168 J. Citation Report)	Reviewer
2015	Present	Register of Expert Peer Reviewers for Italian Scientific Evaluation (REPRISE)	Reviewer

### Part III – Teaching experience

Years	Institution	Lecture/Course
2001-Present	Sapienza University of Rome	Molecular Oncology/Doctorate in Oncology
2002-Present	Sapienza University of Rome	Fundamental of Surgical Pathology/General and Pediatric Nursing (San Pietro Hospital, Rome, Coordinator of the integrated Course)
2002-Present	Sapienza University of Rome	Fundamental of Surgical Pathology/General Nursing (Sant'Andrea Hospital, Rome, Coordinator of the integrated Course)
2002-2005	Thomas Jefferson University, Kimmel Cancer Center, Philadelphia, USA	Molecular Biology of Tumors/School of Medicine.
2003-Present	Sapienza University of Rome	Breast and Female genital tract Pathology/ Graduated school of Pathology
2003-2010	Sapienza University of Rome	Pathology of the Cardiovascular Apparatus/ Graduated school of Cardiac Surgery
2003-Present	Sapienza University of Rome	Molecular Oncology/Graduated school of Oncology

*AW*

2003-Present	Sapienza University of Rome	Pathology of the female genital tract/ Graduated school of Gynecology
2003-2008	Sapienza University of Rome	Pediatric Pathology/School of Medicine.
2003-2008	Sapienza University of Rome	Osteoarticular Pathology/School of Medicine.
2007-2016	Sapienza University of Rome	Molecular Biology/ School of biomedical laboratory technicians.
2008-Present	Sapienza University of Rome	Pathology of the Breast/School of Medicine.
2008-Present	Sapienza University of Rome	Pathology of the female genital tract/School of medicine.
2015-Present	Sapienza University of Rome	Laboratory organization course for Technician/ School of laboratory technicians (Viterbo).
2017-Present	Catholic University of the sacred Heart	Laboratory Techniques/ Graduate School of Pathology

#### Part IV - Society memberships, Awards and Honors

Years	Title
1999-2002	Associate member of the American Association for Cancer Research (AACR)
2002-Present	Active member of the American Association for Cancer Research (AACR)
2002-2004	Member American Association for Investigative Pathology
2005-Present	Member SIAPEC
2007	Outstanding Young Investigator, Sankyo Science Foundation, Japan
2010	Bastianelli Price for Research, Fondazione Roma Sapienza.

#### Part V - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2002	Ruolo del gene oncosoppressore FHIT nei tumori a cellule transizionali della vescica. (Unit Coordinator)	Ministero della salute Finalizzato	50.000,00 €
2003	Role of <i>FEZI</i> gene in the development and progression of Transitional Cell Carcinoma of the urinary bladder (Principal Investigator)	AIRC	65.000,00 €
2003	Eterogeneità molecolare e progressione di malattia nei tumori endocrini dell'apparato digerente (Unit Participant)	PRIN	20.000,00 €
2004	Studio delle cellule di derivazione monocito-macrofagica nell'infiltrato infiammatorio del carcinoma papillare della tiroide e dei tumori prostatici: valutazione del bilancio Arginasi/iNOS e studio dei meccanismi di regolazione. (Unit Participant)	PRIN	30.000,00 €
2004	Genetica molecolare della farmacoresistenza neoplastica e dell'oncogenesi. (Unit Coordinator)	Istituto superiore di Sanità (ISS)	180.000,00 €
2005	Identificazione di fattori prognostici e nuovi markers molecolari nella gestione del paziente con tumore endocrino dell'apparato digerente.	PRIN	25.000,00 €

	<b>(Unit Participant)</b>		
2005	Role of FEZ1/LZTS1 in breast cancer development and its implication in taxol resistance. <b>(Principal Investigator)</b>	AIRC	<b>181.280,00 €</b>
2006	Meccanismi Molecolari e Correlati Anatomo-Patologici, Prognostici e Terapeutici della Formazione della Placca Aterosclerotica Coronarica e della Ristenosi Coronarica. <b>(Unit Coordinator)</b>	Ministero della salute Finalizzato	<b>20.000,00 €</b>
2007	Ruolo del gene oncosoppressore LZTS1 nel carcinoma mammario ( <b>prot. C26F07AHZ9</b> ) <b>(Principal Investigator)</b>	Ateneo Federato Sapienza	<b>10.000,00 €</b>
2008	miRNAs in gastroesophageal malignancies <b>(Principal Investigator)</b>	AIRC	<b>240.000,00 €</b>
2010	Basi molecolari dei processi di carcinogenesi polmonare: caratterizzazione del network trascrizionale e di microRNA a valle delle vie di trasduzione del segnale attive durante lo sviluppo embrionale in cellule staminali tumorali <b>(Unit Coordinator)</b>	PRIN	<b>281.000,00 €</b>
2011	microRNA regulation of drug resistance in ovarian cancer <b>(Principal Investigator)</b>	AIRC	<b>300.000,00 €</b>
2013	Targeting drug resistance in ovarian Cancer <b>(Unit Coordinator)</b>	Ministero della salute Finalizzato	<b>100.000,00 €</b>
2015	Role of microRNA in prostate cancer diagnosis and progression <b>(Principal Investigator)</b>	AIRC	<b>361.000,00 €</b>
2016	La progressione tumorale nei linfomi e nei tumori solidi ( <b>prot. RM116154C901E226</b> ) <b>(Principal Investigator)</b>	Progetti di Ricerca Medi Sapienza	<b>9.800,00 €</b>
2017	Neoplastic progression of solid tumors and lymphomas ( <b>prot. RM11715C815F161B</b> ) <b>(Principal Investigator)</b>	Progetti di Ricerca Medi Sapienza	<b>12.000,00 €</b>

## Part VI – Research Activities

Keywords                      Brief Description

<b>Tumor suppressor genes.</b>	<p>My initial research interests were in tumor suppressor genes. In particular I centered my studies on the <i>FHIT</i> and <i>LZTS1</i> tumor suppressor genes. I was the first one to establish the role of the <i>LZTS1</i> gene in gastric, bladder, Bellini, lung and breast cancers. Then developing the murine knockout of <i>Lzts1</i> I elucidated his instrumental role in the control of cell cycle progression and acquisition of chemoresistance (published on Cancer Cell). During those years I also developed the <i>FHIT</i> and <i>LZTS1</i> recombinant adenoviral vectors, and the <i>Lzts1</i> polyclonal antibody. More recently, since 2004, my interests shifted on a new class of gene regulators the microRNAs. I became immediately attracted to these molecules for some of their innate properties.</p> <p>I was part of the team that together with Dr. Croce developed the microarray platform used to profiles several solid cancers (PNAS, cited 4099 times). My early studies on microRNA focused on gastric cancer where leading of team of young scientist I discovered a new miR cluster (miR-106b-25), which was able to regulate post transcriptionally E2F1 playing a key role in the development of TGFbeta resistance in this neoplasia. This study not only yielded a publication in Cancer Cell (cited 931 times) but I developed and patented a microRNA-based test to predict sensitivity of gastric cancer to therapies. Since then to the present I have been studying the role of miR in different malignancies and their potential applications in diagnosis and prognosis of cancer, and in 2013 I identified a miR-signature capable of discriminating ovarian cancer based on its sensitivity to chemotherapy (PNAS) and in 2018 a signature capable of identify patients with prostate cancer independently from PSA status.</p>
<b>Adenoviral Vectors.</b>	
<b>Mouse models.</b>	
<b>MicroRNA</b>	
<b>Tumor Profiling</b>	
<b>Diagnosis of Cancer</b>	
<b>Prognosis of Cancer</b>	
<b>Breast Cancer</b>	
<b>Gastric Cancer</b>	
<b>Prostate Cancer</b>	

#### Part VII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	91	PubMed	1994	2018
Papers [national]	0	PubMed	1994	2018
Books [scientific]	2	Casa editrice Piccin/Springer Ed.	1997	2011
International Patent	2	Scopus	2008	2013

Total Impact factor	520.12 (Scopus)
Total Citations	8221 (Scopus)
Average Citations per Product	5.8 (Scopus)
Hirsch (H) index	33 (Scopus)
Normalized H index*	1.43 (Scopus)

\*H index divided by the academic seniority.

#### Part VIII– Selected Publications

##### All Publication (from 1994-2018)

1. Giovagnoli M. R., Valli C., **Vecchione A.**, and Vecchione A.



- Immunohistochemical expression of polypeptide specific (TPS) antigen in normal and neoplastic tissue. *Anticancer Res.* 14: 635-642, 1994. **(IF: 1.045 J. Citation Report; Cit: 5 Scopus)**
2. Giarnieri E., Alderisio M., **Vecchione A.**, Forte A., Turano R., Pulcini M. Overexpression of NDP Kinase nm23 associated with ploidy image analysis in colorectal cancer. *Anticancer Res.* 15: 2049-2054, 1995. **(IF: 1.045 J. Citation Report; Cit: 3 Scopus)**
  3. French D., Cermele C., Lombardi A.M., **Vecchione A.**, Midulla C., Del Nero A. and Vecchione A. Microsatellite alterations in Uterine Leiomyomas. *Anticancer Res.* 18: 349-352, 1998. **(IF: 1.236 J. Citation Report; Cit: 6 Scopus)**
  4. Zullo A., Romiti A., Rinaldi V., **Vecchione A.**, Tomao S., Aiuti F., Frati L., Luzi G. Gastric Pathology in common variable immunodeficiency patients. *Gut* 45: 77-81, 1999. **(IF: 5.748 J. Citation Report; Cit: 111 Scopus)**
  5. Baffa R., Gommella L.G., **Vecchione A.**, Bassi P., Sedor J., Calviello C.M., Gardiman M. Minimo C., Strup S.E., McCue P.A., Kovatich A., Pagano F., Hubner K., and Croce C.M. Loss of FHIT expression in Transitional Cell Carcinoma of the Urinary Bladder. *Am J Path* 156: 419-424, 2000. **(IF: 7.103 J. Citation Report; Cit: 69 Scopus)**
  6. French D., Cermele C., **Vecchione A.**, Cenci M., and Vecchione A. HPV infection and Microsatellite Instability in squamous lesions of the uterin cervix. *Anticancer Res.* 20:3417-3421, 2000. **(IF: 1.416 J. Citation Report; Cit: 10 Scopus)**
  7. E. Giarnieri, F. Consorti, A. Lorenzotti, L. Luzzato, G. Soda, **A. Vecchione**, and Giuseppe Midiri. Altered expression of hMSH2 in sporadic colorectal cancer, surrounding and distant colonic mucosa. *Anticancer Res.* 20:3829-3831, 2000. **(IF: 1.416 J. Citation Report; Cit: 2 Scopus)**
  8. H. Ishii, K.R. Dumond, **A. Vecchione**<sup>1</sup>, F. Trapasso, K. Mimori, H. Alder, M. Mori, G. Sozzi, R. Baffa, C.M. Croce. Effect of Adenoviral Trasduction FHIT into Esophageal Cancer Cells. *Cancer Res.* 61:1578-1584, 2001. **Note<sup>1</sup>:H.I, K.D, and A.V. contributed equally to this work. (IF: 8.302 J. Citation Report; Cit: 108 Scopus)**
  9. K. R. Dumon, H. Ishii, L. Y. Y. Fong, N. Zanesi, V. Fidanza, R. Mancini, **A. Vecchione**, R. Baffa, F. Trapasso, M. J. During, K. Huebner, C. M. Croce. Fhit gene Therapy prevents tumor Development in Fhit-deficient Mice. *Proc Natl Acad Sci U S A.* 98: 3346-3351, 2001. **(IF: 10.789 J. Citation Report; Cit: 147 Scopus)**
  10. Zullo A., Romiti A., Rinaldi V., **Vecchione A.**, Hassan C., Winn S., Tomao S., Attili A.F. Gastric epithelial cell proliferation in patients with liver cirrhosis. *Dig Dis Sci.* 46:550-554, 2001. **(IF: 1.867 J. Citation Report; Cit: 19 Scopus)**
  11. **Vecchione A.**, Zanesi N., Trombetta G., French D., Visca P., Pisani T., Botti C., Vecchione A., Croce C.M., R. Mancini. Correlation between Cervical dysplasia, ploidy and HPV status correlate with loss of Fhit expression. *Clinical Cancer Res.* 7:1306-1312, 2001. **(IF: 5.076 J.**



**Citation Report; Cit: 24 Scopus)**

12. **Vecchione A.**, Ishii H., Yih-Horng S., Trapasso F., Rugge M., Tamburrino J.F., Murakamo Y., Alder H., Croce C.M., and Baffa R.. Fez1/Lzts1 alterations in Gastric Carcinoma. *Clinical Cancer Res.* 7: 1546-1522, 2001. **(IF: 5.076 J. Citation Report; Cit: 49 Scopus)**
13. Baldassarre G., Fedele M., Battista, S. **Vecchione A.**, Klein-Szanto A.J.P., Santoro M., Azimi N., Waldman T.A., Croce C.M., Fusco A. Onset of Natural Killer Cell Lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. *Proc Natl Acad Sci U S A.* 98: 7970-7975, 2001. **(IF: 10.896 J. Citation Report; Cit: 76 Scopus)**
14. Dumon K.R., Ishii H., **Vecchione A.**, Trapasso F., Baldassarre G., Chakrani F., Druck T., Rosato E.F., Williams N.N., Baffa R., During M.J., Huebner K., Croce C.M. FHIT expression delays tumor development and induces apoptosis in human pancreatic cancer. *Cancer Res.* 61:4827-4836, 2001. **(IF: 8.302 J. Citation Report; Cit: 100 Scopus)**
15. Ishii H., **Vecchione A.**, Murakumo Y., Baldassarre G., Numata S., Trapasso F., Baffa R., Croce C.M. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. *Proc Natl Acad Sci U S A.* 98(18): 10374-1039, 2001. **(IF: 10.896 J. Citation Report; Cit: 68 Scopus)**
16. Ishii H., Dumon K.R., **Vecchione A.**, Fong L.Y.Y., Baffa R., Huebner K., Croce C.M. Potential cancer therapy with the Fragile Histidine Triad Gene. *JAMA* 286:2441-2449, 2001. **(IF: 21.455 J. Citation Report; Cit: 62 Scopus)**
17. **A. Vecchione**, H. Ishii, G. Baldassarre, P. Bassi, F. Trapasso, H. Alder, F. Pagano, L.G. Gomella, C.M. Croce and R. Baffa. FEZ1/Lzts1 is down regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma (TCC) cells. *Am J Path* 160: 1345-1352, 2002. **(IF: 7.103 J. Citation Report; Cit: 43 Scopus)**
18. Fong L.Y.Y., Ishii H., Nguyen V.T., **Vecchione A.**, Farber JL, Croce C.M., Huebner K. p53 deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice. *Cancer Res.* 63: 186-195, 2003. **(IF: 8.649 J. Citation Report; Cit: 32 Scopus)**
19. Trapasso F., Krakowiak A., Cesari R., Arkles J., Yendamuri S., Ishii H., **Vecchione A.**, Kuroki T., Bieganski P., Pace H.C., Huebner K., Croce C.M., Brenner C. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate-binding. *Proc Natl Acad Sci U S A.* 100: 1592-1597, 2003. **(IF: 10.272 J. Citation Report; Cit: 58 Scopus)**
20. Seignani C., Calin G.A., Cesari R., Sarti M., Ishii H., Yendamuri S., **Vecchione A.**, Trapasso F., Croce C.M. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. *Cancer Res.* 63: 1183-1187, 2003. **(IF: 8.649 J. Citation Report; Cit: 67 Scopus)**

21. **Vecchione A.**, Marchese A., Henry P., Rotin D., Morrione A. Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the IGF-I Receptor. *Mol. Cell Biol.* 23: 3363-3372, 2003. **(IF: 8.142 J. Citation Report; Cit: 181 Scopus)**
22. Ishii H., Zanesi N., **Vecchione A.**, Trapasso F., Yendamuri S., Sarti M., Baffa R., During M.J., Huebner K., Fong L.Y.Y., and Croce C.M. Prevention and regression of upper gastric cancer in mice by FHIT gene therapy. *FASEB J.* 17:1768-1770, 2003. **(IF: 7.172 J. Citation Report; Cit: 50 Scopus)**
23. Ishii H., **Vecchione A.**, Furukawa Y., Sutheesophon K., Han S.Y., Druck T., Kuroki T., Trapasso F., Nishimura M., Saito Y., Ozawa K., Croce C.M., Huebner K., Furukawa Y. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. *Mol Cancer Res.*, 1: 940-947, 2003. **(IF: 2.11 J. Citation Report; Cit: 59 Scopus)**
24. Ishii H., **Vecchione A.**, Fong L.Y.Y., Zanesi N., Trapasso F., Furukawa Y., Baffa R., Huebner K., Croce C.M. Cancer prevention and therapy in a preclinical mouse model: Impact of FHIT viruses. *Current Gene Therapy*, 4. *Curr Gene Ther.* 4: 53-63, 2004. **(IF: new journal J. Citation Report; Cit: 11 Scopus)**
25. Ishii H., Mimori K., **Vecchione A.**, Sutheesophon K., Fujiwara T., Mori M., Furukawa Y. Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX. *Biochemical and Biophysical Research Communications* 316: 1088–1093, 2004. **(IF: 2.93 J. Citation Report; Cit: 10 Scopus)**
26. Morelli C. Garofalo D., Sisci D., Del Rincon S., Cascio S., Tu X., **Vecchione A.**, Sauter E.R., Miller W.H. Jr, Surmacz E. Nuclear Insulin Receptor Substrate 1 Interacts with Estrogen Receptor- at ERE Promoters. *Oncogene* 23: 7517-7522, 2004. **(IF: 6.318 J. Citation Report; Cit: 71 Scopus)**
27. Ishii H., **Vecchione A.**, Furukawa Y., Croce C.M., Huebner K., Fong L.Y.Y. Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats. *Oncogene* 21: 8040-8048, 2004. **(IF: 6.318 J. Citation Report; Cit: 6 Scopus)**
28. Trapasso F., Yendamuri S., Dumon K.R., Iuliano R., Cesari R., Feig B., Infante L., Ishii H., **Vecchione A.**, During M.J., Croce C.M., Fusco A. Restoration of receptor-type protein tyrosine phosphatase function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. *Carcinogenesis* 25: 2107-2114, 2004. **(IF: 5.375 J. Citation Report; Cit: 47 Scopus)**
29. **Vecchione A.**, Ishii H., Giarnieri E., Baldassarre G., Prayer Galetti T., Pagano F., Gomella L.G., Croce C.M. and Baffa R. Clinical-pathological significance of Fez1 protein expression in Bellini duct (collecting duct) carcinoma of the kidney. *BMC Urol.* 4:1-11, 2004. **(IF: New Journal J. Citation Report; Cit: 32 Scopus)**
30. **Vecchione A.**, Sevignani C., Giarnieri E., Zanesi N., Ishii H., Cesari R., Gomella L.G.,



- Croce C.M., and Baffa R. Inactivation of the FHIT gene favors bladder cancer development. *Clinical Cancer Res* 15: 7607-7612, 2004. (IF: 5.623 J. Citation Report; Cit: 30 Scopus)
31. Baldassarre G., Belletti B., Nicoloso M.S., Schiappacassi M., Vecchione A., Spessotto P., Morrione A., Colombatti A. p27<sup>Kip1</sup>-stathmin interaction influences sarcoma cell migration and invasion. *Cancer Cell*. 7:51-63, 2005. (IF: 18.725 J. Citation Report; Cit: 213 Scopus)
32. Nonaka D, Fabbri A., Roz L., Mariani L., Vecchione A., Moore G.W., Tavecchio L., Croce C.M. and Sozzi G. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. *Cancer Res*. 65:1207-1212, 2005. (IF: 7.616 J. Citation Report; Cit: 32 Scopus)
33. Ishii H., Mimori K., Yoshikawa Y., Mori M., Furukawa Y., Vecchione A.. Differential roles of E-type cyclins during transformation of murine E2F-1-deficient cells. *DNA and Cell Biology* 24: 173-179, 2005. (IF: 2.006 J. Citation Report; Cit: 4 Scopus)
34. Ishii H, Mimori K, Inageta T, Murakumo Y, Vecchione A, Mori M, Furukawa Y. Components of DNA Damage Checkpoint Pathway Regulate UV Exposure-Dependent Alterations of Gene Expression of FHIT and WWOX at Chromosome Fragile Sites. *Mol Cancer Res*. 3:130-138, 2005. (IF: 2.11 J. Citation Report; Cit: 20 Scopus)
35. Ishii H., Mimori K., Mori M., Vecchione A.. Differentially expressed genes in endothelial differentiation. *DNA and Cell Biology* 24: 432-437, 2005. (IF: 2.006 J. Citation Report; Cit: 3 Scopus)
36. Zanesi N., Mancini R., Sevignani C., Vecchione A., Kaou M., Valtieri M., Calin G.A., Pekarsky Y., Gnarra J.R., Croce C.M., Huebner K. Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. *Cancer Res*. 65:6576-6582, 2005. (IF: 7.616 J. Citation Report; Cit: 25 Scopus)
37. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M.. A microRNA expression signature of human solid tumors defines cancer genes target. *Proc Natl Acad Sci U S A*. 103: 2257-2261, 2006. (IF: 9.643 J. Citation Report; Cit: 4099 Scopus)
38. Baffa R., Letko J., McClung C., LeNoir J., Vecchione, A., Gomella L.G. Molecular Genetics of bladder cancer: targets for diagnosis and therapy. *J Exp Clin Cancer Res*. 25: 145-160, 2006. (IF: New journal J. Citation Report; Cit: 71 Scopus)
39. Petrocca F., Iliopoulos D., Qin H.R., Nicoloso M.S., Yendamuri S., Wojcik S.E., Shimizu M., Di Leva G., Vecchione A., Trapasso F., Godwin A.K., Negrini M., Calin G.A., Croce C.M. Alterations of the Tumor Suppressor Gene *ARLTS1* in Ovarian Cancer. *Cancer Res*. 66: 10287-10291, 2006. (IF: 7.656 J. Citation Report; Cit: 36 Scopus)
40. Ishii H., Mimori K., Inoue H., Inageta T., Ishikawa K., Semba S., Druck T., Trapasso F., Tani K., Vecchione A., Croce C.M., Mori M., Huebner K. Fhit Modulates the DNA Damage Checkpoint Response. *Cancer Res*. 66: 11287-11292, 2006. (IF: 7.656 J. Citation Report;

AW

**Cit: 33 Scopus)**


41. **Vecchione A.**, Gottardo F., Gomella L.G., Wildemore B., Fassan M., Bragantini E., Pagano F., Baffa R. Molecular Genetics of Prostate Cancer: Mechanisms of Disease Progression. *J Exp Clin Cancer Res* 26: 25-37, 2007. **(IF: New Journal J. Citation Report; Cit: 7 Scopus)**
42. **Vecchione A.**, Baldassarre G., Ishii H., Nicoloso M.S., Belletti B., Petrocca F., Zanesi N., Fong L.Y.Y., Battista S., Guarnieri D., Baffa R., Alder H., Farber J.L., Donovan P.J., Croce C.M.. Fez1/Lzts1 absence impairs Cdk1/cdc25C interaction during mitosis and predispose mice to cancer development. *Cancer Cell* 11: 275-289, 2007. **(IF:23.858 J. Citation Report; Cit: 41 Scopus)**
43. Visone R., Pallante P., **Vecchione A.**, Cirombella R., Ferracin, M., Ferraro A., Volinia S., Coluzzi S., Leone V., Borbone E., Liu C.G., Petrocca F., Troncione G., Calin G.A., Scarpa A., Colato C., Tallini G., Santoro M., Croce C.M., Fusco A. Specific MicroRNAs are downregulated in human thyroid anaplastic carcinomas. *Oncogene* 11:1-6, 2007. **(IF: 6.440 J. Citation Report; Cit: 307 Scopus)**
44. **Vecchione A.**, Croce C.M., Baldassarre G. Fez1/Lzts1 a new mitotic regulator implicated in cancer development. *Cell Div.* 2:24, 2007. **(IF: New Journal J. Citation Report; Cit: 18 Scopus)**
45. Baldassarre G, Croce C.M., **Vecchione A.** Take your "M" time. *Cell Cycle* 6: 2087-2090, 2007. **(IF: 3.314 J. Citation Report; Cit: 3 Scopus)**
46. Baffa R., Fassan M., Sevignani C., **Vecchione A.**, Ishii H., Giarnieri E., Iozzo R.V., Gomella L.G., Croce C.M. Fez1/LZTS1-deficient mice are more susceptible to N-BUTYL-N-(4-HYDROXYBUTYL) Nitrosamine (BBN) carcinogenesis. *Carcinogenesis* 29: 846-848, 2008. IF 5.5 **(IF: 4.930 J. Citation Report; Cit: 14 Scopus)**
47. Petrocca F, Visone R., Rapazzotti Onelli M.A., Manisha S., Nicoloso M.S., De Martino I., Iliopoulos, D. Pillozzi E., Liu C.G., Negrini M., Cavazzini L., Volinia S., Alder H., Ruco L.P., Baldassarre G., Croce C.M., **Vecchione A.** E2F1-regulated MicroRNAs impair TGF $\beta$ -dependent cell cycle arrest and apoptosis in gastric cancer. *Cancer Cell* 13: 272-286, 2008. **(IF: 24.962 J. Citation Report; Cit: 673 Scopus)**
48. Ishii H, Mimori K., Ishikawa K., Okumura H., Pichiorri F., Druck T., Inoue H., **Vecchione A.**, Saito T., Mori M., Huebner K. Fhit-deficient hematopoietic stem cells survive hydroquinone treatment long-term, carrying precancerous alterations. *Cancer Res.* 15: 3662-3670, 2008. **(IF: 7.514 J. Citation Report; Cit: 15 Scopus)**
49. Schiappacassi M., Lovat F., Canzonieri V., Belletti B., Berton S., Di Stefano D., **Vecchione A.**, Colombatti A., Baldassarre G.. p27Kip1 expression inhibits glioblastoma growth, invasion and tumor-induced neoangiogenesis. *Mol Cancer Ter.* 7:1164-1175, 2008. **(IF: 5.003 J. Citation Report; Cit: 38 Scopus)**

50. Petrocca F., **Vecchione A.**, Croce C.M. Emerging role of miR-106b-25/miR-17-92 clusters in the control of TGF $\beta$  signaling. *Cancer Res.* 68:8191-8194, 2008. (**IF: 7.514 J. Citation Report; Cit: 290 Scopus**)
51. **Vecchione A.**, Fassan M., Anesti V., Morrione A., Goldoni S., Baldassarre G., Byrne D., D'arca D., Palazzo J.P., Lloyd J., Scorrano L., Gomella L.G., Iozzo R.V., Baffa R. MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer. *Oncogene* 15:257-269, 2009. (**IF: 7.135 J. Citation Report; Cit: 27 Scopus**)
52. Berton S, Belletti B, Wolf K, Canzonieri V, Lovat F, **Vecchione A**, Colombatti A, Friedl P, Baldassarre G. The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. *Mol Cell Biol.* 29: 5031-5045, 2009. (**IF: 6.057 J. Citation Report; Cit: 45 Scopus**)
53. Andreetti C., D'Andrilli A., Ibrahim M., Poggi C., Maurizi G., **Vecchione A**, Venuta F., Rendina E.A. Submucosal injection of the silver-human albumin complex for the treatment of bronchopleural fistula. *Eur J Cardiothorac Surg.* 37:40-43, 2010. (**IF: 2.293 J. Citation Report; Cit: 10 Scopus**)
54. **Vecchione A**, Croce C.M. Apoptomirs: small molecules have gained the license to kill. *Endocr Relat Cancer.* 17:F37-50, 2010. (**IF: 4.432 J. Citation Report; Cit: 38 Scopus**)
55. Cirombella R., Montrone G., Stoppacciaro A., Giglio S., Volinia S., Graziano P., Huebner K., **Vecchione A**. Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. *Cancer Lett.* 291:230-236, 2010. (**IF: 4.864 J. Citation Report; Cit: 7 Scopus**)
56. Belletti B., Pellizzari I., Berton S., Fabris L., Wolf K., Lovat F., Schiappacassi M., D'Andrea S., Nicoloso M.S., Lovisa S., Sonogo M., Defilippi P., **Vecchione A.**, Colombatti A., Friedl P., Baldassarre G. p27kip1 controls cell morphology and motility by regulating microtubule-dependent lipid raft recycling. *Mol Cell Biol.* 30: 2229-2240, 2010. (**IF: 6.188 J. Citation Report; Cit: 46 Scopus**)
57. Volinia S., Galasso M., Costinean S., Tagliavini L., Gamberoni G., Drusco A., Marchesini J., Mascellani N., Sana M.E., Abu Jarour R., Desponts C., Teitell M., Baffa R., Aqeilan R., Iorio M.V., Taccioli C., Garzon R., Di Leva G., Fabbri M., Catozzi M., Previati M., Ambs S., Palumbo T., Garofalo M., Veronese A., Bottoni A., Gasparini P., Harris C.C., Visone R., Pekarsky Y., De la Chapelle A., Bloomston M., Dillhoff M., Rassenti L.Z., Kipps T.J., Huebner K., Pichiorri F., Lenze D., Cairo S., Buendia M.A., Pineau P., Dejean A., Zanesi N., Rossi S., Calin G.A., Liu C.G., Palatini J., Negrini M., **Vecchione A**, Rosenberg A., Croce C.M. Reprogramming of miRNA networks in cancer and leukemia. *Genome Res.* 20:589-599, 2010. (**IF: 13.588 J. Citation Report; Cit: 252 Scopus**)
58. Del Porto F., Proietta M., Tritapepe L., Miraldi F., Koverech A., Cardelli P., Tabacco F., De Santis V., **Vecchione A.**, Mitterhofer A.P., Nofroni I., Amodeo R., Trappolini M., Aliberti G.


- Inflammation and immune response in acute aortic dissection. *Ann Med.* 42:622-629, 2010. (IF: 4.323 J. Citation Report; Cit: 43 Scopus)
59. Fedele M., Gualillo O, **Vecchione A.** Animal models of human Pathology. *J Biomed Biotechnol* 764618, 2011. (IF: 2.436 J. Citation Report; Cit: 0 Scopus)
60. Fassan M., D'Arca D., Letko J., **Vecchione A.**, Gardiman M.P., McCue P., Wildemore B., Ruge M., Shupp-Byrne D., Gomella L.G., Morrione A, Iozzo R.V., Baffa R. Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. *PLoS One* 6: e19771, 2011. (IF: 4.092 J. Citation Report; Cit: 15 Scopus)
61. Fedele M., Gualillo O., **Vecchione A.** Animal models of human pathology 2012. *J Biomed Biotechnol.* 2012;2012:404130. doi: 10.1155/2012/404130. Epub 2012 Aug 30. (IF: 2.880 J. Citation Report; Cit: 1 Scopus)
62. D'Andrea S., Berton S., Segatto I., Fabris L., Canzonieri V., Colombatti A., **Vecchione A.**, Belletti B., Baldassarre G. Stathmin is dispensable for tumor onset in mice. *PLoS One.* 7:e45561, 2012. (IF: 3.730 J. Citation Report; Cit: 6 Scopus)
63. Cascione L., Gasparini P., Lovat F., Carasi S., Pulvirenti A., Ferro A., Alder H., He G., **Vecchione A.**, Croce C.M., Shapiro C.L., Huebner K. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. *PLoS One.*;8(2):e55910, 2013. (IF: 3.534 J. Citation Report; Cit: 89 Scopus)
64. Giglio S., Cirombella R., Amodeo R., Portaro L., Lavra L., **Vecchione A.** MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a. *J Cell Physiol.* 228: 2015-2023, 2013. (IF: 3.874 J. Citation Report; Cit: 40 Scopus)
65. **Vecchione A.**, Belletti B., Lovat F., Volinia S., Chiappetta G., Giglio S., Sonogo M., Cirombella R., Onesti E.C., Pellegrini P., Califano D., Pignata S., Losito S., Canzonieri V., Sorio R., Alder H., Wernicke D., Stoppacciaro A., Baldassarre G., Croce C.M. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. *Proc Natl Acad Sci U S A.* 110(24):9845-50, 2013. (IF: 9.809 J. Citation Report; Cit: 103 Scopus)
66. Vinciguerra G.L., Mercantini P., La Torre M., Pillozzi E., Ziparo V., **Vecchione A.** Transitional cell carcinoma of the retrorectal space arisen in tailgut cyst: a case report and review of the literature. *Int J Surg Pathol.* 22: 280-285, 2014. (IF: 0.953 J. Citation Report; Cit: 4 Scopus)
67. Segatto I., Berton S., Sonogo M., Massarut S., D'Andrea S., Perin T., Fabris L., Armenia J., Rampioni G.L., Lovisa S., Schiappacassi M., Colombatti A., Bristow R.G., **Vecchione A.**, Baldassarre G., Belletti B. Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. *J Mol Cell Biol.* 5:428-431, 2013. (IF: 8.432 J. Citation Report; Cit: 14 Scopus)
68. Lovat F., Ishii H., Schiappacassi M., Fassan M., Barbareschi M., Galligioni E., Gasparini P., Baldassarre G., Croce C.M., **Vecchione A.** LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. *Oncotarget.* 5:970-977, 2014. (IF: 6.359 J. Citation Report; Cit: 15 Scopus)



69. Lorenzon L., Ziparo V., Caterino S., **Vecchione A.**, Camboni A., Cavallini M. Bilateral cavernous hemangiomas of the adrenal glands: presentation and management of an unusual incidental finding. *Ann Ital Chir.* 84: 693-697, 2013. **(IF: 0.683 J. Citation Report; Cit: 4 Scopus)**
70. Segatto I., Berton S., Sonogo M., Massarut S., Fabris L., Armenia J., Mileto M., Colombatti A., **Vecchione A.**, Baldassarre G., Belletti B. p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. *Mol Oncol.* 8:766-780, 2014. **(IF: 5.331 J. Citation Report; Cit: 18 Scopus)**
71. Fedele M., Gualillo O., **Vecchione A.** Animal models of human pathology 2013. *Biomed Res Int.* 2014:861424. **(IF:3.169 J. Citation Report; Cit: 0 Scopus)**
72. Mrózek E., Layman R., Ramaswamy B., Lustberg M., **Vecchione A.**, Knopp M.V., Shapiro C.L. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. *Clin Breast Cancer.* 14: 228-233, 2014. **(IF: 2.107 J. Citation Report; Cit: 17 Scopus)**
73. Armenia J., Fabris L., Lovat F., Berton S., Segatto I., D'Andrea S., Ivan C., Cascione L., Calin G.A., Croce C.M., Colombatti A., **Vecchione A.**, Belletti B., Baldassarre G. Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. *Oncotarget* 5:1185-1197, 2014. **(IF: 6.359 J. Citation Report; Cit: 10 Scopus)**
74. Segatto I., Berton S., Sonogo M., Massarut S., Perin T., Piccoli E., Colombatti A., **Vecchione A.**, Baldassarre G., Belletti B. Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling. *Oncotarget.* 5:6267-6279, 2014. **(IF: 6.359 J. Citation Report; Cit: 26 Scopus)**
75. Volinia S., Nuovo G., Drusco A., Costinean S., Abujarour R., Desponts C., Garofalo M., Baffa R., Aeqilan R., Maharry K., Sana M.E., Di Leva G., Gasparini P., Dama P., Marchesini J., Galasso M., Manfrini M., Zerbinati C., Corrà F., Wise T., Wojcik S.E., Previati M., Pichiorri F., Zanesi N., Alder H., Palatini J., Huebner K., Shapiro C.L., Negrini M., **Vecchione A.**, Rosenberg A., Croce C.M., Garzon R. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. *J Natl Cancer Inst.* 106 (12), 2014. **(IF: 12.583 J. Citation Report; Cit: 17 Scopus)**
76. Ricciardi E, **Vecchione A.**, Marci R, Schimberni M, Frega A, Maniglio P, Caserta D, Moscarini M. Clinical factors and malignancy in endometrial polyps. Analysis of 1027 cases. *Eur J Obstet Gynecol Reprod Biol.* 183:121-142, 014. **(IF: 1.695 J. Citation Report; Cit: 12 Scopus)**
77. Fedele M, Gualillo O, **Vecchione A.** Animal Models of Human Pathology 2014. *Biomed Res Int.* 2015:721348. **(IF: 2.134 J. Citation Report; Cit: 0 Scopus)**
78. Faruq O, **Vecchione A.** microRNA: Diagnostic Perspective. *Front Med (Lausanne).* 2:51, 2015. **(IF: 1.863 J. Citation Report; Cit: 39 Scopus)**
79. Fabris L, Berton S, Pellizzari I, Segatto I, D'Andrea S, Armenia J, Bomben R, Schiappacassi M, Gattei V, Philips MR, **Vecchione A.**, Belletti B, Baldassarre G. p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. *Proc Natl Acad Sci U S A.* 112:



- 13916-13921, 2015. (IF: 9.423 J. Citation Report; Cit: 18 Scopus)
80. Giglio S, **Vecchione A.** c-Met and miRs in Cancer. *Biomedicines*. 3:32-44, 2015 (IF: NA J. Citation Report; Cit: 2 Scopus)
81. Osman GA, Ricci A, Terzo F, Falasca C, Giovagnoli MR, Bruno P, **Vecchione A**, Raffa S, Valente S, Torrisi MR, De Dominicis C, Giovagnoli S, Mariotta S. Exogenous lipid pneumonia induced by nasal decongestant. *Clin Respir J*. 2016 Sep 22. (IF: 2.356 J. Citation Report; Cit: 2 Scopus)
82. Fedele M, Gualillo O, **Vecchione A.** Animal models of Human Pathology 2016 *Biomed Res Int*. 2016;4023982. (IF: 2.476 J. Citation Report; Cit: 0 Scopus)
83. Citron F, Armenia J, Franchin G, Polesel J, Talamini R, D'Andrea S, Sulfaro S, Croce C.M, Klement W, Pastrello C, Tokar T, Jurisica I, Vaccher E, Serraino D, Belletti B, **Vecchione A\***, Barzan L, and Baldassarre G. A systems approach identifies mediators of local recurrences in Head & Neck Squamous Carcinomas. \* Corresponding Author. *Clin Cancer Res*. 23: 3769-3780, 2017. (IF: 10.199 J. Citation Report; Cit: 3 Scopus)
84. De Nunzio C, Giglio S, Stoppacciaro A, Gacci M, Cirombella R, Luciani E, Tubaro A, **Vecchione A.** Autophagy deactivation is associated with severe prostatic inflammation in patients with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. *Oncotarget*. 8: 50904-50910, 2017. (IF: 4.67 J. Citation Report; Cit: 2 Scopus)
85. Maggi S., Stanzani G., M.D.; Vitale V., **Vecchione A.**, Nania A., Amanti C., Lombardi A. Role of Frozen Section in Sentinel Lymph Node Biopsy for Breast Cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials. *Surgeon*. 2018 Jan 9. pii: S1479-666X(17)30167-1. (IF: 2.096 J. Citation Report; Cit: 0 Scopus)
86. Volinia S, Bertagnolo V, Grassilli S, Brugnoli F, Manfrini M., Galasso M, Scatena C, Mazzanti CM, Lessi F, Naccarato G, Caligo A, Bianchini E, Piubello Q, Orvieto E, Ruggie M, Natali C, Reale D, **Vecchione A**, Warner S, Croce CM, Capitani S. miR-126 and miR-218 are down-regulated in breast ductal carcinoma in situ (DCIS) with invasive properties. *Oncotarget* 9: 23543–23553, 2018. (IF: 4.67 J. Citation Report; Cit: 0 Scopus)
87. Galasso M., Morrison C., Minotti L., Corrà F., Zerbinati C. Agnoletto C.; Baldassari F.; Fassan M.; Bartolazzi A., **Vecchione A.**, Nuovo GJ; Di Leva G., D'Atri S., Alvino E.; Previati M., Nickoloff BJ; Croce C.M., Volinia S. Loss of miR-204 expression is a key event in melanoma. *Mol Cancer*. 17:71, 2018. (IF: 7.776 J. Citation Report; Cit: 1 Scopus)
88. Cocco E, Leo M, Canzonetta C, Di Vito S, Mai A, Rotili D, Di Napoli A, **Vecchione A**, De Nunzio C, Filetici P, Stoppacciaro A. KAT3B-p300 and H3AcK18/H3cK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target KAT inhibitor CPTH2. *Clin Epigenetics*. 10:44. eCollection 2018 (IF: 6.091 J. Citation Report; Cit: 0 Scopus)
89. Coan M, Rampioni G, Cesaratto L, Gardenal E, Bianchet R, Dassi E, **Vecchione A**, Baldassarre G, Spizzo R, Nicoloso MS. Exploring the role of fallopian ciliated cells in the pathogenesis of High Grade Serous Ovarian Cancer. *Int J Mol Sci*. 19(9) 2018. (IF: 3.687 J. Citation



**Report; Cit: 0 Scopus).**

90. Annibaldi V., Umeton R., Palermo A., Severa M., Etna M.P., Giglio S., Romano S., Ferraldeschi M., Buscarinu M.C., **Vecchione A.**, Annese A., Policano C., Mechelli R., Pizzolato Umeton R., Fornasiero A., Angelini D.F., Guerrera G., Battistini L., Coccia E.M., Salvetti M., Ristori G. Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. *J Neuroimmunol.* 324:165-171, 2018 (**IF: 2.655 J. Citation Report; Cit: 0 Scopus**).
91. De Nunzio C, Tema G, Lombardo R, Trucchi A, Bellangino M, Esperto F, Deroma M, Proietti F, **Vecchione A**, Tubaro A. Cigarette smoking is not associated with prostate cancer diagnosis and aggressiveness: a cross sectional italian study. *Minerva Urol Nefrol.* 2018 Sep 19. doi: 10.23736/S0393-2249.18.03182-X. [Epub ahead of print] (**IF: 1.449 J. Citation Report; Cit: 0 Scopus**).

**Book Chapters.**

1. M. F. Cirincione, **A. Vecchione**. Citologia dell' Endometrio, in *Manuale di Citopatologia* Ed. Piccin. 1997. (Italian)
2. T. Pisani, **A. Vecchione**, M.R. Giovagnoli. Citopatologia della Tiroide, in *Manuale di Citopatologia* Ed. Piccin 1997 (Italian)
3. C. Valli, **A. Vecchione**. Tecniche di Citologia, in *Manuale di Citopatologia* Ed Piccin 1997. (Italian)
4. R. Cirombella, **A. Vecchione**. MicroRNA extraction from formalin fixed paraffin embedded tissues, in *Guidelines for Molecular analysis in archive tissues*. Ed. Springer 2011.

**International Patent.**


1. MicroRNA-Based Methods and composition for the diagnosis, prognosis and treatment of gastric cancer WO2009108853A1 (2009; Inventors: C.M. Croce, F. Petrocca, **A. Vecchione**)
2. Methods and materials related to ovarian cancer WO2013056217A1 (2013; Inventors: C.M. Croce, **A. Vecchione**)

**Part IX— Selected Publications (nr. 16 last 10 years)**

1. Petrocca F, Visone R., Rapazzotti Onelli M.A., Manisha S., Nicoloso M.S., De Martino I., Iliopoulos, D. Pilozzi E., Liu C.G., Negrini M., Cavazzini L., Volinia S., Alder H., Ruco L.P., Baldassarre G., Croce C.M., **Vecchione A.** E2F1-regulated MicroRNAs impair TGF $\beta$ -dependent cell cycle arrest and apoptosis in gastric cancer. *Cancer Cell* 13: 272-286, 2008. (**IF: 24.962 J. Citation Report; Cit: 673 Scopus**)
2. **Vecchione A.**, Fassan M., Anesti V., Morrione A., Goldoni S., Baldassarre G., Byrne D., D'arca D., Palazzo J.P., Lloyd J., Scorrano L., Gomella L.G., Iozzo R.V., Baffa R. MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in



- human bladder and breast cancer. *Oncogene* 15: 257-269, 2009. (IF: 7.135 J. Citation Report; Cit: 27 Scopus)
3. **Vecchione A**, Croce C.M. Apoptomirs: small molecules have gained the license to kill. *Endocr Relat Cancer*. 17:F37-50, 2010. (IF: 4.432 J. Citation Report; Cit: 38 Scopus)
  4. Cirombella R., Montrone G., Stoppacciaro A., Giglio S., Volinia S., Graziano P., Huebner K., **Vecchione A**. Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. *Cancer Lett*. 291: 230-236, 2010. (IF: 4.864 J. Citation Report; Cit: 7 Scopus)
  5. Giglio S., Cirombella R., Amodeo R., Portaro L., Lavra L., **Vecchione A**. MicroRNA miR-24 promotes cell proliferation by targeting the CDKs inhibitors p27Kip1 and p16INK4a. *J Cell Physiol*. 228: 2015-23, 2013. (IF: 3.874 J. Citation Report; Cit: 40 Scopus)
  6. **Vecchione A.**, Belletti B., Lovat F., Volinia S., Chiappetta G., Giglio S., Sonogo M., Cirombella R., Onesti E.C., Pellegrini P., Califano D., Pignata S., Losito S., Canzonieri V., Sorio R., Alder H., Wernicke D., Stoppacciaro A., Baldassarre G., Croce C.M. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. *Proc Natl Acad Sci U S A*. 110: 9845-9850, 2013. (IF: 9.809 J. Citation Report; Cit: 103 Scopus)
  7. Segatto I., Berton S., Sonogo M., Massarut S., D'Andrea S., Perin T., Fabris L., Armenia J., Rampioni G.L., Lovisa S., Schiappacassi M., Colombatti A., Bristow R.G., **Vecchione A.**, Baldassarre G., Belletti B. Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. *J Mol Cell Biol*. 5: 428-431, 2013. (IF: 8.432 J. Citation Report; Cit: 14 Scopus)
  8. Vinciguerra G.L., Mercantini P., La Torre M., Pillozzi E., Ziparo V., **Vecchione A**. Transitional cell carcinoma of the retrorectal space arisen in tailgut cyst: a case report and review of the literature. *Int J Surg Pathol*. 22: 280-285, 2014. (IF: 0.953 J. Citation Report; Cit: 4 Scopus)
  9. Lovat F., Ishii H., Schiappacassi M., Fassan M., Barbareschi M., Galligioni E., Gasparini P., Baldassarre G., Croce C.M., **Vecchione A**. LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. *Oncotarget*. 5: 970-977, 2014. (IF: 6.359 J. Citation Report; Cit: 15 Scopus)
  10. Armenia J., Fabris L., Lovat F., Berton S., Segatto I., D'Andrea S., Ivan C., Cascione L., Calin G.A., Croce C.M., Colombatti A., **Vecchione A.**, Belletti B., Baldassarre G. Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. *Oncotarget* 5: 1185-1197, 2014. (IF: 6.359 J. Citation Report; Cit: 10 Scopus)
  11. Segatto I., Berton S., Sonogo M., Massarut S., Perin T., Piccoli E., Colombatti A., **Vecchione A.**, Baldassarre G., Belletti B. Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling. *Oncotarget*. 5: 6267-6279, 2014. (IF: 6.359 J. Citation Report; Cit: 26 Scopus)
  12. Volinia S., Nuovo G., Drusco A., Costinean S., Abujarour R., Despons C., Garofalo M., Baffa R., Aeqilan R., Maharry K., Sana M.E., Di Leva G., Gasparini P., Dama P., Marchesini J., Galasso M., Manfrini M., Zerbinati C., Corrà F., Wise T., Wojcik S.E., Previati M., Pichiorri F., Zanesi N.,



- Alder H., Palatini J., Huebner K., Shapiro C.L., Negrini M., **Vecchione A.**, Rosenberg A., Croce C.M., Garzon R. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. *J Natl Cancer Inst.* 2014 Oct 11;106. **(IF: 12.583 J. Citation Report; Cit: 17 Scopus)**
13. Faruq O, **Vecchione A.** microRNA: Diagnostic Perspective. *Front Med (Lausanne)*. 2:51, 2015. **(IF: 1.863 J. Citation Report; Cit: 39 Scopus)**
14. Fabris L, Berton S, Pellizzari I, Segatto I, D'Andrea S, Armenia J, Bomben R, Schiappacassi M, Gattei V, Philips MR, **Vecchione A.**, Belletti B, Baldassarre G. p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability. *Proc Natl Acad Sci U S A.* 112: 13916-1321, 2015. **(IF: 9.423 J. Citation Report; Cit: 18 Scopus)**
15. Citron F, Armenia J, Franchin G, Polesel J, Talamini R, D'Andrea S, Sulfaro S, Croce C.M, Klement W, Pastrello C, Tokar T, Jurisica I, Vaccher E, Serraino D, Belletti B, **Vecchione A\***, Barzan L, and Baldassarre G. A systems approach identifies mediators of local recurrences in Head & Neck Squamous Carcinomas. \* **Corresponding Author.** *Clin Cancer Res.* 23: 3769-3780, 2017. **(IF: 10.199 J. Citation Report; Cit: 3 Scopus)**
16. De Nunzio C, Giglio S, Stoppacciaro A, Gacci M, Cirombella R, Luciani E, Tubaro A, **Vecchione A.** Autophagy deactivation is associated with severe prostatic inflammation in patients with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. *Oncotarget.* 8:50904-50910, 2017. **(IF: 4.67 J. Citation Report; Cit: 2 Scopus)**

Roma 28/11/2018

In Fede

Andrea Vecchione

